Herceptin prolongs overall survival in the right kind of breast cancerBMJ 2007; 334 doi: http://dx.doi.org/10.1136/bmj.334.7584.67-b (Published 11 January 2007) Cite this as: BMJ 2007;334:67
We already know that the monoclonal antibody trastuzumab (Herceptin) prevents or at least delays the recurrence of breast cancer in the 15-25% of women with early disease whose cancers express the HER2 transmembrane growth factor receptor. The latest analysis of data from …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial